Alderley Park-based Aptus Clinical Ltd today announced that recruitment has started on the innovative COSMIC-19 study, which they believe will help transform and shape clinical trial monitoring in the future. COSMIC-19 study (COntinuous Signs Monitoring in Covid-19 patients), sponsored by The Christie NHS Foundation Trust in collaboration with Manchester University Foundation NHS Trust, utilises advanced...
Read our white paper on the clinical development challenges in oncology
According to the largest analysis of almost 7,500 clinical and regulatory phase transitions, the likelihood of an oncology drug progressing from Phase I clinical testing is 5%, the lowest of the 14 major disease areas analysed. Of the oncology drugs that do progress, twice as many are for haematological malignancies than for solid tumours.1 Despite...
Aptus Clinical and Alderley Park benefit from Northern Powerhouse Investment Fund
The Northern Powerhouse Investment Fund which is delivered by British Business Bank, has invested a total of £2.5m into businesses based at Alderley Park, Cheshire, the UK’s largest single site life science campus. The £2.5m invested into businesses at Alderley Park forms part of NPIF’s £10m milestone that was recently achieved in the Cheshire and...
Day in the Life – Louise Scott, Director of Clinical Operations
“If you relish a challenge, then Aptus Clinical is definitely the company for you” says Louise Scott, recently promoted to Associate Director of Clinical Operations at Aptus Clinical. Louise joined the company a year ago and was first attracted to it by the opportunity to help shape a newly formed Clinical Operations department. Founded in...
Day in the Life – Risk Governance and Compliance Director, Tessa Clarke
“If I were a superhero, I’d definitely be the Juggling Queen”, says Tessa Clarke, Risk, Governance and Compliance Lead at Aptus Clinical. Fortunately for Tessa, her close colleagues all presented something similar when asked to draw their superhero talent at a recent training day. “The fact that Debbie drew a plate spinner made me chuckle...
Day in the Life – Contracts and Proposals Manager, Will Rose
“Since joining Aptus Clinical I achieve in a few days what used to take me several months”, says Will Rose, Contracts and Proposals Manager at Aptus Clinical. Will joined the Business Development team a year ago with no prior experience of the pharmaceutical or CRO sector. In fact, he had spent the previous 10 years...
Design of innovative FiH study: CellCentric
Design of Innovative FiH Study CellCentric Planning a Route ForwardPlanning a First in Human (FiH) study The ChallengeCellCentric approached Aptus Clinical to assist them in designing their First in Human (FiH) study for their lead project, a small molecule inhibitor of p300/CBP The SolutionAptus Clinical convened a multi-disciplinary panel of medical, scientific and technical experts...
Renaissance of interest in medicines modulating ECS: Rising to the challenge
The body’s endocannabinoid system (ECS) consists of receptors and chemical messengers located in the central and peripheral nervous system, forming a biochemical communication network throughout the body that regulates a variety of physiological and cognitive processes. Drugs that modify the activity of endocannabinoids such as cannabinoid receptor agonists and antagonists, agents modifying cannabinoid transport, or...
Aptus Clinical selected as clinical CRO by Artelo Biosciences
Aptus Clinical has been appointed full service clinical CRO partner by Artelo Biosciences Inc. (through their fully owned UK subsidiary, Trinity R&D Ltd.) to deliver the upcoming Phase 1B/2A trial of their synthetic cannabinoid, ART27.13. This latest agreement builds on an earlier research and development partnership agreement, where Aptus successfully designed and supported the critical...
Development of an operationally feasible clinical pharmacology package
Development of an operationally feasible clinical pharmacology package US Biotech Case Study Development of Pharmacology Programme For Lead Oncology Asset The ChallengeAptus Clinical was asked by a US-based Biotech to assess whether the clinical pharmacology programme for their lead oncology asset could be conducted in healthy volunteers rather than patients The SolutionAn expert panel was...